Exact Mass: 534.2518
Exact Mass Matches: 534.2518
Found 322 metabolites which its exact mass value is equals to given mass value 534.2518
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6))
PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0)
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
N,N-bis[2-[(2-chlorobenzyl)-diethyl-ammonio]ethyl]oxalimidate
3beta,6alpha-dihydroxy-1alpha,7beta,11beta,15beta-tetraacetoxy-6,18-cyclo-ent-kaur-16-ene|nervonin A
(3E,7E)-2alpha,10beta,13alpha,20-tetraacetoxy-5alpha-hydroxy-3,8-secotaxa-3,7,11-trien-9-one
(22SR,23SR,24RS,25SR)-12alpha,22:21,24-diepoxy-5alpha,6beta,12beta,17beta,25-pentahydroxy-1-oxo-with-2-en-26,23-olide|jaborosalactone 35
asterriquinone dimethyl ether
A member of the class of asterriquinones that is asterriquinone in which the hydrogens of both of the hydroxy groups have replaced by methyl groups.
2alpha,5alpha,7beta,13alpha-tetraacetoxy-10beta-hydroxyl-2(3->20)abeotaxan-9-one|2??,5??,7??,13??-Tetraacetoxy-10??-hydroxy-2(3鈥樏傗垎20)abeotaxan-9-one
(1R*,2R*,3S*,5Z,7S*,8S*,9S*,10S*,11Z,14S*,17R*)-2,14-diacetoxy-3-butyrloxy-8,17-epoxy-9-hydroxybriara-5,11-dien-18-one
(3E,7E)-2alpha,5alpha,10beta,13alpha-tetraacetoxy-20-hydroxy-3,8-secotaxa-3,7,11-trien-9-one
Bulleyanin
2??-Acetoxy-4??-hydroxy-6??-p-hydroxybenzoyloxy-10??-benzoyloxy-dauc-8-ene
C28H38O10_Methyl 5-acetoxy-6,10-dihydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylene-1,4,8-trioxohexadecahydro-2H-naphtho[1,2-h]isochromene-2-carboxylate
C28H38O10_1H-Pyrano[3,4:5,6]naphth[2,1-c]oxepin-3,8,11(9H)-trione, 5,12-bis(acetyloxy)dodecahydro-13-hydroxy-1,1,5a,7a,9,11b-hexamethyl-7-methylene
Cys Glu Lys Arg
Cys Glu Arg Lys
Cys Lys Glu Arg
Cys Lys Arg Glu
Cys Arg Glu Lys
Cys Arg Lys Glu
Asp Lys Ser Trp
Asp Lys Trp Ser
Asp Ser Lys Trp
Asp Ser Trp Lys
Asp Trp Lys Ser
Asp Trp Ser Lys
Glu Cys Lys Arg
Glu Cys Arg Lys
Glu His His Ile
Glu His His Leu
Glu His Ile His
Glu His Leu His
Glu Ile His His
Glu Lys Cys Arg
Glu Lys Met Gln
Glu Lys Gln Met
Glu Lys Arg Cys
Glu Leu His His
Glu Met Lys Gln
Glu Met Gln Lys
Glu Gln Lys Met
Glu Gln Met Lys
Glu Arg Cys Lys
Glu Arg Lys Cys
His Glu His Ile
His Glu His Leu
His Glu Ile His
His Glu Leu His
His His Glu Ile
His His Glu Leu
His His Ile Glu
His His Leu Glu
His Ile Glu His
His Ile His Glu
His Leu Glu His
His Leu His Glu
Ile Glu His His
Ile His Glu His
Ile His His Glu
Lys Cys Glu Arg
Lys Cys Arg Glu
Lys Asp Ser Trp
Lys Asp Trp Ser
Lys Glu Cys Arg
Lys Glu Met Gln
Lys Glu Gln Met
Lys Glu Arg Cys
Lys Met Glu Gln
Lys Met Gln Glu
Lys Gln Glu Met
Lys Gln Met Glu
Lys Arg Cys Glu
Lys Arg Glu Cys
Lys Ser Asp Trp
Lys Ser Trp Asp
Lys Trp Asp Ser
Lys Trp Ser Asp
Leu Glu His His
Leu His Glu His
Leu His His Glu
Met Glu Lys Gln
Met Glu Gln Lys
Met Lys Glu Gln
Met Lys Gln Glu
Met Gln Glu Lys
Met Gln Lys Glu
Met Gln Arg Thr
Met Gln Thr Arg
Met Arg Gln Thr
Met Arg Thr Gln
Met Thr Gln Arg
Met Thr Arg Gln
Pro Gln Gln Tyr
Pro Gln Tyr Gln
Pro Tyr Gln Gln
Gln Glu Lys Met
Gln Glu Met Lys
Gln Lys Glu Met
Gln Lys Met Glu
Gln Met Glu Lys
Gln Met Lys Glu
Gln Met Arg Thr
Gln Met Thr Arg
Gln Pro Gln Tyr
Gln Pro Tyr Gln
Gln Gln Pro Tyr
Gln Gln Tyr Pro
Gln Arg Met Thr
Gln Arg Thr Met
Gln Thr Met Arg
Gln Thr Arg Met
Gln Thr Thr Trp
Gln Thr Trp Thr
Gln Trp Thr Thr
Gln Tyr Pro Gln
Gln Tyr Gln Pro
Arg Cys Glu Lys
Arg Cys Lys Glu
Arg Glu Cys Lys
Arg Glu Lys Cys
Arg Lys Cys Glu
Arg Lys Glu Cys
Arg Met Gln Thr
Arg Met Thr Gln
Arg Gln Met Thr
Arg Gln Thr Met
Arg Ser Ser Trp
Arg Ser Trp Ser
Arg Thr Met Gln
Arg Thr Gln Met
Arg Trp Ser Ser
Ser Asp Lys Trp
Ser Asp Trp Lys
Ser Lys Asp Trp
Ser Lys Trp Asp
Ser Arg Ser Trp
Ser Arg Trp Ser
Ser Ser Arg Trp
Ser Ser Trp Arg
Ser Trp Asp Lys
Ser Trp Lys Asp
Ser Trp Arg Ser
Ser Trp Ser Arg
Thr Met Gln Arg
Thr Met Arg Gln
Thr Gln Met Arg
Thr Gln Arg Met
Thr Gln Thr Trp
Thr Gln Trp Thr
Thr Arg Met Gln
Thr Arg Gln Met
Thr Thr Gln Trp
Thr Thr Trp Gln
Thr Trp Gln Thr
Thr Trp Thr Gln
Trp Asp Lys Ser
Trp Asp Ser Lys
Trp Lys Asp Ser
Trp Lys Ser Asp
Trp Gln Thr Thr
Trp Arg Ser Ser
Trp Ser Asp Lys
Trp Ser Lys Asp
Trp Ser Arg Ser
Trp Ser Ser Arg
Trp Thr Gln Thr
Trp Thr Thr Gln
Tyr Pro Gln Gln
Tyr Gln Pro Gln
Tyr Gln Gln Pro
(1R,2R)-N,N-Dihydroxy-N,N-bis(diphenylacetyl)cyclohexane-1,2-diamine
(1S,2S)-N,N-Dihydroxy-N,N-bis(diphenylacetyl)cyclohexane-1,2-diamine
Acetamide, N-[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]-N-[4-[[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]amino]butyl]-
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury[1][2][3].
longirostrerone D
A natural product found in Chaetomium longirostre. An azaphilone that is 6H-furo[2,3-h]isochromene-6,8(6aH)-dione substituted by a 4-hydroxy-2-methyl-6-oxocyclohexyl group at position 3, a methyl group at position 6a, and a 4,6,8-trimethyldeca-2,4-dienoyl group at position 9. Isolated from Chaetomium longirostre, it exhibits cytotoxic activities.
(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[3-[(8S,9R,10S,13R,14R,17S)-17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoyloxy]oxane-2-carboxylic acid
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
(6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(1r,3s,4s,5r,7s,8r,9s,10z,12s,13s,14s)-4,8,9-tris(acetyloxy)-3,6,6,10,14-pentamethyl-2-oxo-16-oxatetracyclo[10.3.1.0¹,¹².0⁵,⁷]hexadec-10-en-13-yl acetate
(1e,3s,4s,6s,9r,11s,12s,14s)-3,9,12-tris(acetyloxy)-14-hydroxy-7,11,16,16-tetramethyl-10-oxotricyclo[9.3.1.1⁴,⁸]hexadeca-1,7-dien-6-yl acetate
4,8,9-tris(acetyloxy)-3,6,6,10,14-pentamethyl-2-oxo-16-oxatetracyclo[10.3.1.0¹,¹².0⁵,⁷]hexadec-10-en-13-yl acetate
3-amino-2-hydroxy-n-[(6s,7r)-7,10,10-trimethyl-12-(2-methylpropyl)-2,5,9,11-tetraoxo-3-(sec-butyl)-1,4,8-trioxacyclododecan-6-yl]benzenecarboximidic acid
n-[7-(butanoyloxy)-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-3-yl]-2-hydroxy-3-[(hydroxymethylidene)amino]benzenecarboximidic acid
(3r,4r,5s,7s,10s,11r,13s)-7,10,13-tris(acetyloxy)-3-hydroxy-4,14,15,15-tetramethyl-2-oxotricyclo[9.3.1.1⁴,⁸]hexadeca-1(14),8-dien-5-yl acetate
(1r,2r,3r,4r,6s,8s,9r,10s,11s,13r)-2,3,8-tris(acetyloxy)-6-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl acetate
[2,10,13-tris(acetyloxy)-5-hydroxy-8,12,15,15-tetramethyl-9-oxobicyclo[9.3.1]pentadeca-3,7,11-trien-4-yl]methyl acetate
2,5-dimethoxy-3-[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]-6-[1-(2-methylbut-3-en-2-yl)indol-3-yl]cyclohexa-2,5-diene-1,4-dione
(1s,2s,3r,5s,7r,8s,9s,10s,11r,15s)-3,10,15-tris(acetyloxy)-9-hydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-7-yl acetate
(1r,2r,3r,5s,7s,8s,9r,10r)-2,9,10-tris(acetyloxy)-5-hydroxy-8,12,15,15-tetramethyl-4-methylidene-13-oxotricyclo[9.3.1.0³,⁸]pentadec-11-en-7-yl acetate
6,7',11'-tris(acetyloxy)-3,3-dimethyl-10'-methylidene-2'-oxo-3'-oxaspiro[cyclohexane-1,5'-tricyclo[7.2.1.0¹,⁶]dodecan]-2-ylmethyl acetate
(6as)-3-[(1s,2s,4r)-4-hydroxy-2-methyl-6-oxocyclohexyl]-6a-methyl-9-[(2e)-4,6,8-trimethyldeca-2,4-dienoyl]furo[2,3-h]isochromene-6,8-dione
2α,5α,7β,13α-tetraacetoxy-10β-hydroxy-2(3→20)abeotaxan-9-one
{"Ingredient_id": "HBIN005246","Ingredient_name": "2\u03b1,5\u03b1,7\u03b2,13\u03b1-tetraacetoxy-10\u03b2-hydroxy-2(3\u219220)abeotaxan-9-one","Alias": "NA","Ingredient_formula": "C28H38O10","Ingredient_Smile": "CC1=C2C(C(=O)C3(CC(=CC(C(C2(C)C)CC1OC(=O)C)OC(=O)C)C(CC3OC(=O)C)OC(=O)C)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21013","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}